Cancer Med

Better blood pressure regimens linked to improved survival in metastatic breast cancer

March 3, 2026

In a cohort of 1,332 women with de novo metastatic breast cancer, 48.4% had hypertension overall and 64.6% among Black women. During follow‑up, 52.9% received antihypertensives (20.3% monotherapy; 32.5% polytherapy). Polytherapy was associated with lower all‑cause mortality (21.4 vs. 28.5 per 100 person years) and a 38% reduction in mortality risk (hazard ratio [HR] 0.62; 95% confidence interval [CI], 0.47–0.82). Protection was strongest in Hispanic patients (HR, 0.40; 95% CI, 0.20–0.84) and suggested in Black patients (HR, 0.48; 95% CI, 0.22–1.05). Breast cancer–specific mortality also decreased with polytherapy, especially with good adherence (HR, 0.43; 95% CI, 0.24–0.77).

Clinical takeaway: Prioritize aggressive and consistent hypertension management—including consideration of polytherapy—to help reduce mortality risk in patients with metastatic breast cancer.

Source:

Haque R, et al. (2026, February 26). Cancer Med. Influence of Hypertension Management on Survival in Patients With Metastatic Breast Cancer. https://pubmed.ncbi.nlm.nih.gov/41744234/